Home/Pipeline/Atopic Dermatitis Program

Atopic Dermatitis Program

Atopic Dermatitis

Pre-clinicalActive

Key Facts

Indication

Atopic Dermatitis

Phase

Pre-clinical

Status

Active

Company

Lxbio Pharmaceuticals

About Lxbio Pharmaceuticals

Lxbio Pharmaceuticals is an emerging, private biotech company based in Lisbon, Portugal, operating in the high-growth sectors of antibody and bacteriophage therapies. It is developing a pre-clinical pipeline targeting therapeutic areas with significant unmet needs, including diabetic foot infections, ocular surface infections, atopic dermatitis, respiratory infections, and diabetic retinopathy. The company has made strategic infrastructure investments, inaugurating a dedicated biologics R&D and production unit, and is actively seeking investment to advance its innovative platforms and pipeline programs.

View full company profile

Therapeutic Areas

Infectious Disease Ophthalmology Dermatology Metabolic Disease

Other Atopic Dermatitis Drugs

Drug	Company	Phase	Status
PEP Biologic™	Intent Biologics	Unknown	Active
HBM7575 (SKB575)	Harbour BioMed	IND Filed	Active (Global)
ITK inhibitor	Acellera	Pre-clinical	Hit-to-Lead
ENS-002 (Fermata Derm)	Concerto Biosciences	Pre-clinical	Active
Lead Program	MatriSys Bioscience	Phase 1	Active
Atopic Dermatitis Trial	Well Pharma Medical Research	Not Specified	Active
MEndoB	Micreos	Pre-clinical	Active
B244	AOBiome	Phase 3	Active
CTO1681	CytoAgents	Pre-clinical	Active
DS107	DS Biopharma	Phase 2	Active
AX-158	Artax Biopharma	Phase 2	Active
NM26	Numab Innovation	Pre-clinical	Active